Honghong Zhou
Overview
Explore the profile of Honghong Zhou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
12055
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xu J, Peng H, Kuang R, Han Z, Zhou H, Hu M, et al.
Genomics
. 2025 Jan;
117(2):110998.
PMID: 39855485
Intramuscular fat is an essential component of muscle tissue, and understanding its contribution to skeletal muscle fat infiltration and meat quality, together with the underlying genetic mechanisms, is a major...
2.
Follmann D, Wang X, Baden L, El Sahly H, Essink B, Gilbert P, et al.
Open Forum Infect Dis
. 2024 Dec;
11(12):ofae689.
PMID: 39679349
Background: To help inform COVID-19 vaccination recommendations, we evaluated the impact of age and dosing interval on clinical benefit of a third dose of mRNA-1273. Methods: Approximately 17 000 participants...
3.
Goswami J, Cardona J, Hsu D, Simorellis A, Wilson L, Dhar R, et al.
Lancet Infect Dis
. 2024 Nov;
PMID: 39608389
Background: Coadministration of a respiratory syncytial virus (RSV) vaccine with seasonal influenza or SARS-CoV-2 vaccines could reduce health-care visits and increase vaccination uptake in older adults who are at high...
4.
Ivaturi V, Attarwala H, Deng W, Ding B, Schnyder Ghamloush S, Girard B, et al.
CPT Pharmacometrics Syst Pharmacol
. 2024 Sep;
14(1):42-51.
PMID: 39327773
COVID-19 vaccines, including mRNA-1273, have been rapidly developed and deployed. Establishing the optimal dose is crucial for developing a safe and effective vaccine. Modeling and simulation have the potential to...
5.
Zhang B, Fong Y, Fintzi J, Chu E, Janes H, Kenny A, et al.
Nat Commun
. 2024 Sep;
15(1):7954.
PMID: 39261482
In the phase 3 Coronavirus Efficacy (COVE) trial (NCT04470427), post-dose two Ancestral Spike-specific binding (bAb) and neutralizing (nAb) antibodies were shown to be correlates of risk (CoR) and of protection...
6.
Priddy F, Chalkias S, Essink B, Whatley J, Brosz A, Lee I, et al.
Expert Rev Vaccines
. 2024 Sep;
23(1):862-878.
PMID: 39234779
Introduction: Vaccination against SARS-CoV-2 is an integral pillar of the public health approach to COVID-19. With the emergence of variants of concern that increase transmissibility and escape from vaccine- or...
7.
Baden L, El Sahly H, Essink B, Follmann D, Hachigian G, Strout C, et al.
Nat Commun
. 2024 Aug;
15(1):7469.
PMID: 39209823
Primary vaccination with mRNA-1273 (100-µg) was safe and efficacious at preventing coronavirus disease 2019 (COVID-19) in the previously reported, blinded Part A of the phase 3 Coronavirus Efficacy (COVE; NCT04470427)...
8.
Berthaud V, Creech C, Rostad C, Carr Q, de Leon L, Dietrich M, et al.
Clin Infect Dis
. 2024 Aug;
79(6):1524-1532.
PMID: 39158584
Background: A 2-dose mRNA-1273 primary series in children aged 6 months-5 years (25 µg) and 6-11 years (50 µg) had an acceptable safety profile and was immunogenic in the phase...
9.
Figueroa A, Ali K, Berman G, Zhou H, Deng W, Xu W, et al.
EClinicalMedicine
. 2024 Aug;
74:102720.
PMID: 39091673
Background: Longitudinal changes in vaccination-induced immune response remain inadequately characterized in adolescents. We present long-term safety, immunogenicity, and COVID-19 incidence following a 2-dose mRNA-1273 100-μg primary series, and immunogenicity following...
10.
Goswami J, Baqui A, Doreski P, Marc G, Jimenez G, Ahmed S, et al.
J Infect Dis
. 2024 Jun;
230(5):e996-e1006.
PMID: 38889247
Background: The mRNA-1345 vaccine demonstrated efficacy against respiratory syncytial virus (RSV) disease with acceptable safety in adults aged ≥60 years in the ConquerRSV trial. Here, humoral immunogenicity results from the...